Details for Patent: 7,361,650
✉ Email this page to a colleague
Which drugs does patent 7,361,650 protect, and when does it expire?
Patent 7,361,650 protects CORLANOR and is included in two NDAs.
Protection for CORLANOR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-eight patent family members in forty-one countries.
Summary for Patent: 7,361,650
| Title: | .gamma.-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
| Abstract: | A .gamma.-Crystalline form of ivabradine hydrochloride of formula (I): ##STR00001## characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics. |
| Inventor(s): | Horvath; Stephane (La Chapelle-Saint-Mesmin, FR), Auguste; Marie-Noelle (Orleans, FR), Damien; Gerard (Meung-sur-Loire, FR) |
| Assignee: | Les Laboratoires Servier (Courbevoie Cedex, FR) |
| Application Number: | 11/358,955 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,361,650 |
|
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Use; |
Drugs Protected by US Patent 7,361,650
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc | CORLANOR | ivabradine | SOLUTION;ORAL | 209964-001 | Apr 22, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE | ⤷ Try a Trial | ||
| Amgen Inc | CORLANOR | ivabradine hydrochloride | TABLET;ORAL | 206143-001 | Apr 15, 2015 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Amgen Inc | CORLANOR | ivabradine hydrochloride | TABLET;ORAL | 206143-002 | Apr 15, 2015 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,361,650
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| France | 05.01989 | Feb 28, 2005 |
International Family Members for US Patent 7,361,650
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 1956 | ⤷ Try a Trial | |||
| Argentina | 052926 | ⤷ Try a Trial | |||
| Austria | E396974 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
